MCID: HDG002
MIFTS: 42

Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

MalaCards integrated aliases for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

Name: Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance 12 15
Hodgkin Disease 43 71
Hodgkin Lymphoma, Lymphocytic-Histiocytic Predominance 12
Hodgkin's Disease, Lymphocyte Predominance 12
Lymphocyte Rich Classical Hodgkin Lymphoma 71
Hodgkin Lymphoma, Lymphocyte-Rich 12
Lymphocyte Rich Hodgkin's Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8543
ICD9CM 34 201.4
MeSH 43 D006689
NCIt 49 C6913
SNOMED-CT 67 118607005
ICD10 32 C81.4
UMLS 71 C0019829 C1266194

Summaries for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

MalaCards based summary : Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance, also known as hodgkin disease, is related to lymphoma, hodgkin, classic and gastrointestinal lymphoma, and has symptoms including fever and night sweats. An important gene associated with Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance is FUT4 (Fucosyltransferase 4), and among its related pathways/superpathways are NF-kappaB Signaling and Mannose type O-glycan biosynthesis. The drugs Etoposide and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are hematopoietic system and immune system

Related Diseases for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Diseases related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 33.1 TNFRSF8 PTPRC BCL6
2 gastrointestinal lymphoma 29.7 TNFRSF8 BCL6
3 b-cell lymphoma 29.6 TNFRSF8 PTPRC BCL6
4 histiocytosis 29.6 TNFRSF8 PTPRC
5 reticulum cell sarcoma 29.5 TNFRSF8 PTPRC
6 lymphoma, non-hodgkin, familial 29.4 TNFRSF8 PTPRC BCL6
7 angioimmunoblastic t-cell lymphoma 29.4 TNFRSF8 BCL6
8 composite lymphoma 29.4 TNFRSF8 FUT4 BCL6
9 lymphosarcoma 29.3 TNFRSF8 PTPRC BCL6
10 immune deficiency disease 29.2 TNFRSF8 PTPRC BCL6
11 diffuse large b-cell lymphoma 29.1 TNFRSF8 PTPRC BCL6
12 small cell carcinoma 28.9 PTPRC B3GAT1
13 leukemia, acute myeloid 28.8 TNFRSF8 PTPRC FUT4 BCL6
14 classic hodgkin lymphoma, lymphocyte-rich type 12.9
15 lymphoma, hodgkin, x-linked pseudoautosomal 11.8
16 sarcoidosis 1 11.5
17 lymphoma, hodgkin, y-linked pseudoautosomal 11.5
18 lymphoma 11.5
19 lymphoproliferative syndrome 1 11.2
20 hodgkin's paragranuloma 11.2
21 hodgkin's granuloma 11.2
22 hodgkin's lymphoma, lymphocytic depletion 10.3 TNFRSF8 FUT4
23 mediastinal malignant lymphoma 10.3 TNFRSF8 FUT4
24 mediastinal gray zone lymphoma 10.3 TNFRSF8 FUT4
25 pleural lipoma 10.2 TNFRSF8 FUT4
26 congenital granular cell tumor 10.2 FUT4 B3GAT1
27 uterus leiomyosarcoma 10.2 TNFRSF8 FUT4
28 nodular lymphocyte predominant hodgkin lymphoma 10.2 TNFRSF8 BCL6
29 lung lymphoma 10.2 TNFRSF8 BCL6
30 t-cell/histiocyte rich large b cell lymphoma 10.2 TNFRSF8 BCL6
31 paranasal sinus lymphoma 10.2 TNFRSF8 BCL6
32 breast lymphoma 10.2 TNFRSF8 BCL6
33 pediatric lymphoma 10.1 TNFRSF8 BCL6
34 tracheal lymphoma 10.1 TNFRSF8 BCL6
35 autoimmune lymphoproliferative syndrome, type v 10.1 TNFRSF8 BCL6
36 leukemia 10.1
37 adult lymphoma 10.1 TNFRSF8 BCL6
38 nephrotic syndrome 10.1
39 testicular lymphoma 10.1 TNFRSF8 BCL6
40 ataxia and polyneuropathy, adult-onset 10.1
41 deficiency anemia 10.1
42 thrombocytopenia 10.1
43 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.1 TNFRSF8 PTPRC
44 breast lipoma 10.1 TNFRSF8 PTPRC
45 breast cancer 10.1
46 anemia, autoimmune hemolytic 10.1
47 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.1
48 neutropenia 10.1
49 hemolytic anemia 10.1
50 acquired immunodeficiency syndrome 10.1

Graphical network of the top 20 diseases related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:



Diseases related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Symptoms & Phenotypes for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

UMLS symptoms related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:


fever, night sweats

MGI Mouse Phenotypes related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.43 BCL6 FUT4 JCHAIN NINL PTPRC TNFRSF8
2 immune system MP:0005387 9.1 BCL6 FUT4 JCHAIN PHYH PTPRC TNFRSF8

Drugs & Therapeutics for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Drugs for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 352)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 4 33419-42-0 36462
2
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
3
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Epirubicin Approved Phase 4 56420-45-2 41867
9
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
10 Etoposide phosphate Phase 4
11 Gastrointestinal Agents Phase 4
12 Hormones Phase 4
13 Antiemetics Phase 4
14 Hormone Antagonists Phase 4
15 glucocorticoids Phase 4
16 Anti-Inflammatory Agents Phase 4
17 Methylprednisolone Acetate Phase 4
18 Protective Agents Phase 4
19 Neuroprotective Agents Phase 4
20
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
21
Panobinostat Approved, Investigational Phase 3 404950-80-7 6918837
22
Ichthammol Approved Phase 3 8029-68-3
23
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
24
Chlorambucil Approved Phase 3 305-03-3 2708
25
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 12560 441411
26
Aldesleukin Approved Phase 2, Phase 3 85898-30-2, 110942-02-4
27
Daunorubicin Approved Phase 3 20830-81-3 30323
28
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
29
rituximab Approved Phase 3 174722-31-7 10201696
30
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
31
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
32
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
33
Gemcitabine Approved Phase 3 95058-81-4 60750
34
Vinblastine Approved Phase 3 865-21-4 241903 13342
35
Ifosfamide Approved Phase 3 3778-73-2 3690
36
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
38
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
39
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
40
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
41
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
42
Melphalan Approved Phase 3 148-82-3 460612 4053
43
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
44
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
45
Cortisone Experimental Phase 3 53-06-5 222786
46
Mitoguazone Investigational Phase 3 459-86-9
47 Hematinics Phase 3
48 Epoetin alfa Phase 3 113427-24-0
49 Norgestimate, ethinyl estradiol drug combination Phase 3
50 Fluorodeoxyglucose F18 Phase 3

Interventional clinical trials:

(show top 50) (show all 703)
# Name Status NCT ID Phase Drugs
1 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
2 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab vedotin
3 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
4 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
5 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Active, not recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
6 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
7 Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease Unknown status NCT00002462 Phase 3 doxorubicin hydrochloride;mechlorethamine hydrochloride;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
8 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
9 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
10 BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma Unknown status NCT00049595 Phase 3 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
11 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
12 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma Unknown status NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
13 Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) Completed NCT00443677 Phase 3 COPPEBVCAD vs BEACOPP vs ABVD
14 Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Completed NCT00038558 Phase 3 Filgrastim SD/01;Adriamycin;Bleomycin;Vinblastine;DTIC
15 HD12 for Advanced Stages Completed NCT00265031 Phase 3 Cyclophosphamide;Adriamycin;Etoposide;Procarbazine;Prednisone;Vincristine;Bleomycin
16 HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma Completed NCT01356680 Phase 3 BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone);ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
17 HD10 for Early Stages Completed NCT00265018 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC
18 HD11 for Intermediate Stages Completed NCT00264953 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC;Etoposide;Procarbazine;Prednisone;Vincristine
19 Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed NCT00398411 Phase 3 moxifloxacin;placebo
20 A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment Completed NCT01854567 Phase 3
21 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy Completed NCT00039910 Phase 3 (PN-152,243)/ PN-196,444
22 A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
23 Randomized Phase III Study of a Treatment Driven by Early PET Response Compared to a Treatment Not Monitored by Early PET in Patients With Ann Arbor Stage III-IV or High Risk IIB Hodgkin Lymphoma Completed NCT01358747 Phase 3 BEACOPPesc;BEACOPPesc - ABVD - PET2
24 Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy Completed NCT01085058 Phase 2, Phase 3 lenograstim
25 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT) Completed NCT01034163 Phase 3 Panobinostat;Placebo
26 A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease Completed NCT00302003 Phase 3 doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide;ifosfamide;vinorelbine tartrate;dexamethasone;etoposide phosphate;cisplatin;cytarabine
27 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Completed NCT01188798 Phase 3 Methotrexate;Pentostatin
28 Randomized Trial of Subtotal Nodal Irradiation Versus Doxorubicin, Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease Completed NCT00002495 Phase 3 doxorubicin hydrochloride;vinblastine
29 Early Salvage With High Dose Chemotherapy and Stem Cell Transplantation in Advanced Stage Hodgkin's Lymphoma Patients With Positive PET After Two Courses of ABVD (PET-2 Positive) and Comparison of RT Versus no RT in PET-2 Negative Patients Completed NCT00784537 Phase 2, Phase 3 ABVD;ABVD and Radiotherapy
30 Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study Completed NCT00005578 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
31 A UKLG Randomised Trial of Initial Chemotherapy for Advanced Stage Hodgkins Disease Completed NCT00003421 Phase 3 ABVD regimen;chlorambucil;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
32 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
33 Plerixafor and G−CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non−Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) − Safety Study in a General Autologous Transplant Population Completed NCT00838357 Phase 3 Generic = Plerixafor
34 Prospective Randomized Comparison of ABVD Versus BEACOPP Chemotherapy With or Without Radiotherapy for Advanced Stage or Unfavorable Hodgkin's Lymphoma (HL) Completed NCT01251107 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
35 RESPONSE DEPENDENT TREATMENT OF STAGES IA, IIA AND IIIA HODGKIN'S DISEASE WITH DBVE AND LOW DOSE INVOLVED FIELD IRRADIATION WITH OR WITHOUT ZINECARD: A PEDIATRIC ONCOLOGY GROUP PHASE III STUDY Completed NCT00002827 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;vincristine sulfate
36 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) on Anemia and Quality of Life in Children With Cancer Undergoing Myelosuppressive Chemotherapy Completed NCT00261677 Phase 3 epoetin alfa
37 A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy Completed NCT00469729 Phase 2, Phase 3 StemEx®
38 The H10 EORTC/GELA/IIL Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Supradiaphragmatic Stage I/II Hodgkin's Lymphoma Completed NCT00433433 Phase 3 ABVD q4 weeks;BEACOPP escalated q3 weeks
39 A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy Versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease Completed NCT00002561 Phase 3 dacarbazine;doxorubicin hydrochloride;vinblastine
40 A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease Completed NCT00070187 Phase 2, Phase 3 carmustine;cyclosporine;cytarabine;etoposide;melphalan
41 First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
42 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of the Sintilimab Plus ICE Regimen Versus Placebo Plus ICE Regimen in the Classic Hodgkin's Lymphoma Patients With First-line Standard Chemotherapy Failure Recruiting NCT04044222 Phase 3 Carboplatin;Etoposide;Ifosfamide;Placebo;Carboplatin;Etoposide;Ifosfamide
43 HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD Recruiting NCT02661503 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Brentuximab Vedotin;Dacarbazine;Dexamethasone
44 Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease Recruiting NCT01951885 Phase 3 tacrolimus;methotrexate;Mycophenolate mofetil;Methotrexate (low dose)
45 European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents Recruiting NCT02684708 Phase 3 cyclophosphamide, vincristine, prednisone, dacarbazine;cyclo, vcr, pred, dacarb,etop and doxo
46 A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL). Recruiting NCT03159897 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
47 A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Recruiting NCT03907488 Phase 3 Brentuximab Vedotin;Dacarbazine;Doxorubicin;Doxorubicin Hydrochloride;Vinblastine;Vinblastine Sulfate
48 HD18 for Advanced Stages in Hodgkins Lymphoma Active, not recruiting NCT00515554 Phase 3 Rituximab;BEACOPP escalated
49 HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET Active, not recruiting NCT00736320 Phase 3 ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)
50 Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812) Active, not recruiting NCT03138499 Phase 3

Search NIH Clinical Center for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: hodgkin disease

Genetic Tests for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Anatomical Context for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

MalaCards organs/tissues related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

40
T Cells, B Cells, Bone, Bone Marrow, Breast, Lung, Liver

Publications for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Articles related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

(show top 50) (show all 1459)
# Title Authors PMID Year
1
Outcome at the end of treatment of patients with common and curable childhood cancer types in Blantyre, Malawi. 61
32391955 2020
2
Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. 61
32098890 2020
3
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas. 61
32407544 2020
4
The physiological and pathological roles and applications of sialyl Lewis x, a common carbohydrate ligand of the three selectins. 61
32062824 2020
5
Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. 61
32143684 2020
6
[Paraneoplastic subacute degeneration of the cerebellum in non-small cell lung cancer and positive anti-Tr3 antibodies]. 61
31900515 2020
7
Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact. 61
32457824 2020
8
Multidetector computed tomography evaluation of synchronous lymphoma and other solid malignancies. 61
32362610 2020
9
Primary diffuse large B-cell lymphoma of mandible masquerading as a toothache. 61
31792469 2020
10
Cancer Risk in Klippel-Trenaunay Syndrome. 61
31045469 2019
11
[Autoimmune hemolytic anemia and immune thrombocytopenia associated with Hodgkin disease: Retrospective monocentric study]. 61
31668883 2019
12
The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments. 61
30458690 2019
13
Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation. 61
31707719 2019
14
Epithelial cell infection by Epstein-Barr virus. 61
31584659 2019
15
Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation. 61
31170519 2019
16
Characteristics and Survival Outcomes of Children With Hodgkin Lymphoma Treated Primarily With Chemotherapy. 61
31033793 2019
17
Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. 61
30322329 2019
18
Prevalence of deaths in a cohort of girls and women with cryopreserved ovarian tissue. 61
30770545 2019
19
Hepatic Manifestations of Lymphoproliferative Disorders. 61
30947878 2019
20
Primary adrenal Hodgkin lymphoma. 61
30899496 2019
21
Proton beam therapy in pediatric oncology. 61
30531222 2019
22
Acrokeratosis Can Be a Warning Sign of an Underlying Malignancy. 61
31157185 2019
23
Interest of FDG-PET in the Management of Mantle Cell Lymphoma. 61
31024918 2019
24
Unusual occurrence of avascular necrosis with bilateral involvement and ankylosing spondylitis, meningioma and Hodgkin lymphoma. 61
31912115 2019
25
Presentation and Outcomes of Childhood Cancer Patients at Uganda Cancer Institute. 61
31205984 2019
26
Paracoccidioides brasiliensis Infection Mimicking Recurrent Hodgkin Lymphoma: A Case Report and Review of the Literature. 61
29476307 2018
27
Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma. 61
30358625 2018
28
Vaccine-induced immune thrombocytopaenia purpura in autologous haematopoietic stem cell transplantation. 61
30647224 2018
29
Novel Pilot Curriculum for International Education of Lymphoma Management Using E-Contouring. 61
30241149 2018
30
Long-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysis. 61
30112841 2018
31
Bone loss and hematological malignancies in adults: a pilot study. 61
29549514 2018
32
Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies. 61
29616457 2018
33
F-18 FDG PET-CT Versus Contrast Enhanced CT in Detection of Extra Nodal Involvement in Patients with Lymphoma. 61
29962712 2018
34
A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency. 61
29644723 2018
35
l-Asparaginase: a feasible therapeutic molecule for multiple diseases. 61
29872609 2018
36
Is Carotid Stiffness a Possible Surrogate for Stroke in Long-term Survivors of Childhood Cancer after Neck Radiotherapy? 61
30018516 2018
37
FDG Accumulation in the Lumen of the Gallbladder Without Related Pathology. 61
29485432 2018
38
Granulomatous Lymphangitis Masquerading as Relapsed Hodgkin Disease on FDG PET/CT. 61
30042982 2018
39
Evidence for the association of Epstein-Barr Virus in breast cancer in Indian patients using in-situ hybridization technique. 61
28557251 2018
40
Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. 61
29339629 2018
41
Acquired reactive perforating collagenosis associated with Hodgkin disease. 61
28691303 2017
42
Feasibility and Acceptability of a Web Site to Promote Survivorship Care in Survivors of Hodgkin Disease. 61
30657382 2017
43
Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational 18F-FDG PET/CT Observation. 61
28646013 2017
44
Idiopathic Thrombocytopenia Purpura Masking Hodgkin Disease: A Paraneoplastic Syndrome or Simply a Mere Association? 61
29430236 2017
45
Head and Neck Lymphoma in an Iranian Population. 61
31328112 2017
46
Head and Neck Lymphoma in an Iranian Population. 61
29034220 2017
47
Hematologic Malignancies Are Associated With Adverse Perioperative Outcomes After Total Hip Arthroplasty. 61
28372919 2017
48
Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis. 61
28272287 2017
49
Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. 61
28143714 2017
50
Pulmonary toxicity following bleomycin use: A single-center experience. 61
28862210 2017

Variations for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Expression for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Search GEO for disease gene expression data for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance.

Pathways for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Pathways related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.65 TNFRSF8 PTPRC BCL6
2 9.98 FUT4 B3GAT1

GO Terms for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Cellular components related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell periphery GO:0071944 8.62 PTPRC FUT4

Biological processes related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 B cell differentiation GO:0030183 8.96 PTPRC BCL6
2 positive regulation of B cell proliferation GO:0030890 8.62 PTPRC BCL6

Sources for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....